Key clinical point: HER2-mutant non–small cell lung cancer (NSCLC) is associated with a high incidence of brain metastases.
Major finding: About 28% of patients with HER2-mutated NSCLC developed brain metastases on treatment versus 8% of patients with KRAS-mutated NSCLC.
Study details: A retrospective record review of 98 patients with HER2-mutant NSCLC, and 200 each with KRAS- or EGFR-mutant NSCLC.
Disclosures: The study was supported by the National Institutes of Health through a National Cancer Institute Cancer Center support grant and by the Eloise Briskin Foundation. Dr. Offin reported honoraria from Bristol-Myers Squibb, Merck, PharmaMar, Novartis, and Targeted Oncology. Multiple coauthors had similar disclosures.
Offin M et al. Cancer. 2019 Aug 30. doi: 10.1002/cncr.32461.